A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages

Journal of Inflammation

Volumn 5, Issue , 2008, Pages

  Turnbull, Catriona M ^a   Marcarino, Paolo ^b   Sheldrake, Tara A ^d   Lazzarato, Loretta ^b   Cena, Clara ^b   Fruttero, Roberta ^b   Gasco, Alberto ^b   Fox, Sarah ^d   Megson, Ian L ^c   Rossi, Adriano G ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; DEXAMETHASONE; FURAZAN DERIVATIVE; FUROXAN ACETYLSALICYLIC ACID; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; NITRIC OXIDE DONOR; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; NUCLEAR LOCALIZATION SIGNAL; WESTERN BLOTTING;

EID: 50249156491     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-5-12     Document Type: Article

References (74)

1. The mechanism of action of aspirin. JR Vane RM Botting, Thromb Res 2003 110 255 258 10.1016/S0049-3848(03)00379-7 14592543
2. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. DL DeWitt WL Smith, Proc Natl Acad Sci USA 1988 85 1412 1416 3125548 10.1073/pnas.85.5.1412
3. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. GJ Roth PW Majerus, J Clin Invest 1975 56 624 632 1159076 10.1172/JCI108132
4. Acetylation of prostaglandin synthase by aspirin. GJ Roth N Stanford PW Majerus, Proc Natl Acad Sci USA 1975 72 3073 3076 810797 10.1073/pnas.72.8.3073
5. Aspirin and gastric ulcer. AJ Cameron, Mayo Clin Proc 1975 50 565 570 1165647
6. ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs. JM Seager CJ Hawkey, Bmj 2001 323 1236 1239 11719417 10.1136/bmj.323.7323.1236
7. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. MR Tramer RA Moore DJ Reynolds HJ McQuay, Pain 2000 85 169 182 10.1016/S0304-3959(99)00267-5 10692616
8. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. JL Wallace, Gastroenterology 1997 112 1000 1016 10.1053/gast.1997.v112.pm9041264 9041264
9. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. A Robert JE Nezamis C Lancaster AJ Hanchar, Gastroenterology 1979 77 433 443 456839
10. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. RT Schoen RJ Vender, Am J Med 1989 86 449 458 10.1016/0002-9343(89)90344-6 2648824
11. Mechanisms underlying gastric mucosal damage induced by indomethacin and bile-salts, and the actions of prostaglandins. BJ Whittle, Br J Pharmacol 1977 60 455 460 890212
12. Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. C Cena ML Lolli L Lazzarato E Guaita G Morini G Coruzzi SP McElroy IL Megson R Fruttero A Gasco, J Med Chem 2003 46 747 754 10.1021/jm020969t 12593655
13. NO-aspirin: mechanism of action and gastrointestinal safety. S Fiorucci P Del Soldato, Dig Liver Dis 2003 35 Suppl 2 S9 19 10.1016/S1590-8658(03)00047-1 12846439
14. Nitric oxide in mucosal defense: a little goes a long way. JL Wallace MJ Miller, Gastroenterology 2000 119 512 520 10.1053/gast.2000.9304 10930387
15. Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. JF Brown AC Keates PJ Hanson BJ Whittle, Am J Physiol 1993 265 G418 422 8214062
16. Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. L Ma JL Wallace, Am J Physiol Gastrointest Liver Physiol 2000 279 G341 346 10915643
17. Gastric irritancy of aspirin and its congeners: anti-inflammatory activity without this side-effect. KD Rainsford MW Whitehouse, J Pharm Pharmacol 1976 28 599 601 8621
18. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. JL Wallace W McKnight P Del Soldato AR Baydoun G Cirino, J Clin Invest 1995 96 2711 2718 8675638 10.1172/JCI118338
19. Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets. CM Turnbull C Cena R Fruttero A Gasco AG Rossi IL Megson, Br J Pharmacol 2006 148 517 526 16702997 10.1038/sj.bjp.0706743
20. Nitric oxide as a regulator of inflammatory processes. JL Wallace, Mem Inst Oswaldo Cruz 2005 100 Suppl 1 5 9 15962091
21. Chemokines, a family of chemotactic cytokines. DT Graves Y Jiang, Crit Rev Oral Biol Med 1995 6 109 118 7548618
22. Comparison of the intoxication pathways of tumor necrosis factor and diphtheria toxin. MP Chang BJ Wisnieski, Infect Immun 1990 58 2644 2650 2370113
23. Stimulation of neutrophils by tumor necrosis factor. SJ Klebanoff MA Vadas JM Harlan LH Sparks JR Gamble JM Agosti AM Waltersdorph, J Immunol 1986 136 4220 4225 3009619
24. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. CA Dinarello JG Cannon SM Wolff HA Bernheim B Beutler A Cerami IS Figari MA Palladino Jr JV O'Connor, J Exp Med 1986 163 1433 1450 3486936 10.1084/jem.163.6.1433
25. The NF-kappa B and I kappa B proteins: new discoveries and insights. AS Baldwin Jr, Annu Rev Immunol 1996 14 649 683 10.1146/annurev.immunol.14.1.649 8717528
26. Nitric oxide and intestinal inflammation. P Kubes DM McCafferty, Am J Med 2000 109 150 158 10.1016/S0002-9343(00)00480-0 10967157
27. A novel member of the Ikappa B family, human Ikappa B-zeta, inhibits transactivation of p65 and its DNA binding. G Totzke F Essmann S Pohlmann C Lindenblatt RU Janicke K Schulze-Osthoff, J Biol Chem 2006 16513645
28. Mechanisms underlying the enhanced elevation of IL-1beta and TNF-alpha mRNA levels following endotoxin challenge in rat alveolar macrophages cultured with low-Mg2+ medium. H Oono M Nakagawa A Miyamoto S Ishiguro A Nishio, Magnes Res 2002 15 153 160 12635866
29. An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs. S Laufer C Greim T Bertsche, Osteoarthritis Cartilage 2002 10 961 967 10.1053/joca.2002.0851 12464556
30. The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers. MW Bleeker MG Netea BJ Kullberg J Van der Ven-Jongekrijg JW Van der Meer, Immunology 1997 91 548 552 9378493 10.1046/j.1365-2567.1997.00285.x
31. Corticosteroid effects on cell signalling. PJ Barnes, Eur Respir J 2006 27 413 426 10.1183/09031936.06.00125404 16452600
32. Glucocorticoids: effects on gene transcription. IM Adcock K Ito PJ Barnes, Proc Am Thorac Soc 2004 1 247 254 10.1513/pats.200402-001MS 16113442
33. New insights into the molecular mechanisms of corticosteroids actions. IM Adcock G Caramori K Ito, Curr Drug Targets 2006 7 649 660 10.2174/ 138945006777435344 16787166
34. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. M Hachicha M Pouliot NA Petasis CN Serhan, J Exp Med 1999 189 1923 1930 10377187 10.1084/jem.189.12.1923
35. NO suppresses while peroxynitrite sustains NF-kappaB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO. Y Hattori K Kasai SS Gross, Cardiovasc Res 2004 63 31 40 10.1016/j.cardiores.2004.03.014 15194459
36. Relevance of platelet-independent effects of aspirin to its salutary effect in atherosclerosis-related events. Q Khan JL Mehta, J Atheroscler Thromb 2005 12 185 190 16141621
37. Inhibition of NF-kappa B by sodium salicylate and aspirin. E Kopp S Ghosh, Science 1994 265 956 959 10.1126/science.8052854 8052854
38. Inhibition of NF-kappaB DNA binding by nitric oxide. JR Matthews CH Botting M Panico HR Morris RT Hay, Nucleic Acids Res 1996 24 2236 2242 8710491 10.1093/nar/24.12.2236
39. Inhibition of NF-kappaB and HIV-1 long terminal repeat transcriptional activation by inducible nitric oxide synthase 2 activity. D Sekkai F Aillet N Israel M Lepoivre, J Biol Chem 1998 273 3895 3900 10.1074/jbc.273.7.3895 9461573
40. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. I Tegeder J Pfeilschifter G Geisslinger, FASEB J 2001 15 2057 2072 10.1096/fj.01-0390rev 11641233
41. NF-kappaB, nitric oxide and opiate signaling. ID Welters C Fimiani TV Bilfinger GB Stefano, Med Hypotheses 2000 54 263 268 10.1054/mehy.1999.0032 10790762
42. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. MJ Yin Y Yamamoto RB Gaynor, Nature 1998 396 77 80 10.1038/23948 9817203
43. NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. C Ward ER Chilvers MF Lawson JG Pryde S Fujihara SN Farrow C Haslett AG Rossi, J Biol Chem 1999 274 4309 4318 10.1074/jbc.274.7.4309 9933632
44. Regulation of macrophage phagocytosis of apoptotic cells by cAMP. AG Rossi JC McCutcheon N Roy ER Chilvers C Haslett I Dransfield, J Immunol 1998 160 3562 3568 9531319
45. Monocyte Functional Responsiveness After PSGL-1-Mediated Platelet Adhesion Is Dependent on Platelet Activation Status. S Bournazos J Rennie SP Hart KA Fox I Dransfield, Arterioscler Thromb Vasc Biol 2008 28 8 1491 1498 10.1161/ATVBAHA.108.167601 18497306
46. Oncostatin M promotes biphasic tissue factor expression in smooth muscle cells: evidence for Erk-1/2 activation. T Nishibe G Parry A Ishida S Aziz J Murray Y Patel S Rahman K Strand K Saito Y Saito, Blood 2001 97 692 699 10.1182/blood.V97.3.692 11157486
47. Inhibition of the nuclear factor-kappaB signaling pathway by leflunomide or triptolide also inhibits the anthralin-induced inflammatory response but does not affect keratinocyte growth inhibition. H Feng XY Li JR Zheng JW Gao LF Xu MY Tang, Biol Pharm Bull 2005 28 1597 1602 10.1248/bpb.28.1597 16141522
48. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. JA Mitchell M Saunders PJ Barnes R Newton MG Belvisi, Mol Pharmacol 1997 51 907 912 9187256
49. Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alfa (TNF-alpha) in human monocytes. LT Osnes KB Foss GB Joo C Okkenhaug AB Westvik R Ovstebo P Kierulf, Thromb Haemost 1996 76 970 976 8972019
50. NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes. P Minuz M Degan S Gaino A Meneguzzi V Zuliani CL Santonastaso PD Soldato A Lechi, Br J Pharmacol 2001 134 905 911 11606332 10.1038/sj.bjp.0704326
51. Plasma concentrations and anti-platelet effects after low dose acetylsalicylic acid. B Rosenkranz JC Frolich, Prostaglandins Leukot Med 1985 19 289 300 10.1016/0262-1746(85)90142-8 3864170
52. IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. S Fiorucci L Santucci G Cirino A Mencarelli L Familiari PD Soldato A Morelli, J Immunol 2000 165 5245 5254 11046058
53. Differential responses of human monocytes and macrophages to IL-4 and IL-13. PH Hart CS Bonder J Balogh HL Dickensheets RP Donnelly JJ Finlay-Jones, J Leukoc Biol 1999 66 575 578 10534111
54. Mature macrophage cell lines exhibit variable responses to LPS. SE Barbour C Wong D Rabah A Kapur AD Carter, Mol Immunol 1998 35 977 987 10.1016/S0161-5890(98)00070-4 9881693
55. MAP kinase activation in macrophages. KM Rao, J Leukoc Biol 2001 69 3 10 11200064
56. Changes in PKC isoforms in human alveolar macrophages compared with blood monocytes. MM Monick AB Carter G Gudmundsson LJ Geist GW Hunninghake, Am J Physiol 1998 275 L389 397 9700101
57. Macrophage and monocyte IL-1 beta regulation differs at multiple sites. Messenger RNA expression, translation, and post-translational processing. DJ Herzyk JN Allen CB Marsh MD Wewers, J Immunol 1992 149 3052 3058 1401931
58. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. A Panwalkar S Verstovsek F Giles, Cancer 2004 100 1578 1589 10.1002/cncr.20182 15073843
59. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. S Ghosh MJ May EB Kopp, Annu Rev Immunol 1998 16 225 260 10.1146/annurev.immunol.16.1.225 9597130
60. IkappaB kinases: key regulators of the NF-kappaB pathway. Y Yamamoto RB Gaynor, Trends Biochem Sci 2004 29 72 79 10.1016/j.tibs.2003.12.003 15102433
61. Activation of NF-kappa B by reactive oxygen intermediates in the nervous system. B Kaltschmidt T Sparna C Kaltschmidt, Antioxid Redox Signal 1999 1 129 144 10.1089/ars.1999.1.2-129 11228742
62. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. H Liu P Sidiropoulos G Song LJ Pagliari MJ Birrer B Stein J Anrather RM Pope, J Immunol 2000 164 4277 4285 10754326
63. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. HL Pahl B Krauss K Schulze-Osthoff T Decker EB Traenckner M Vogt C Myers T Parks P Warring A Muhlbacher, J Exp Med 1996 183 1829 1840 8666939 10.1084/jem.183.4.1829
64. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile]. A Carroccio L Di Prima G Pirrone G Ambrosiano D Noto AB Cefalu, Recenti Prog Med 2006 97 108 112 quiz 122. 16671277
65. Joint inflammation and cytokine inhibition in rheumatoid arthritis. C Christodoulou EH Choy, Clin Exp Med 2006 6 13 19 10.1007/s10238-006-0088-5 16550339
66. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. C Russo R Polosa, Clin Sci (Lond) 2005 109 135 142 16033328
67. Spotlight on infliximab in Crohn disease and rheumatoid arthritis. MA Siddiqui LJ Scott, BioDrugs 2006 20 67 70 10.2165/00063030-200620010-00008 16573354
68. Therapeutic effects of nitric oxide-aspirin hybrid drugs. CM Turnbull AG Rossi IL Megson, Expert Opin Ther Targets 2006 10 911 922 10.1517/14728222.10.6. 911 17105376
69. Atherosclerosis - an inflammatory disease. R Ross, N Engl J Med 1999 340 115 126 10.1056/NEJM199901143400207 9887164
70. Cytokines and endothelial cell biology. JS Pober RS Cotran, Physiol Rev 1990 70 427 451 1690903
71. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. P Libby G Sukhova RT Lee ZS Galis, J Cardiovasc Pharmacol 1995 25 Suppl 2 S9 12 8699871
72. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. ZS Galis M Muszynski GK Sukhova E Simon-Morrissey EN Unemori MW Lark E Amento P Libby, Circ Res 1994 75 181 189 8013077
73. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. YJ Geng Q Wu M Muszynski GK Hansson P Libby, Arterioscler Thromb Vasc Biol 1996 16 19 27 8548421
74. DNA fragmentation and ultrastructural changes of degenerating cells in atherosclerotic lesions and smooth muscle cells exposed to oxidized LDL in vitro. S Jovinge M Crisby J Thyberg J Nilsson, Arterioscler Thromb Vasc Biol 1997 17 2225 2231 9351393